3 research outputs found
Effectiveness of unani regimen in protecting high risk population from COVID -19: A pilot study
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally. COVID-19 presents varied clinical features. The present study focuses on number of patients turning COVID-19 positive, change in Immune Status Questionnaire (ISQ) and WHO quality of life- Bref (WHO Qol – BREF) scales after taking intervention. This open labelled, double arm, controlled, interventional, clinical trial was conducted on high-risk individuals i.e., those residing with a COVID-19 positive member in the identified quarantine area. This twin armed study was conducted on asymptomatic individuals exposed to COVID -19. The test group were prescribed Unani poly-herbal decoction together with Unani formulations Khamira Marwareed and Tiryaq e Arba whereas the control group was not on any intervention. The duration of intervention was 20 days; follow ups were planned on day 10 and day 20. Of the 81 participants enrolled, none of the patients turned COVID-19 positive. However, 13.58% (n=11) developed COVID like symptoms and 70 patients completed the study. The mean age of the participants was 41.42±16.9 years; however, majority of the participants were 18-28 years male with Damvi (Sanguine) temperament. The quality of life of the intervention group improved significantly however, the immune status in both the groups increased with P <0.001. The Unani prophylactic regimen provides a 62% (relative risk reduction) protection against COVID -19. This pilot study paves for a study on a larger population. No adverse effects were observed during the study. Absence of biochemical investigations were limitations to the study
Application of Sol–Gels for Treatment of Gynaecological Conditions—Physiological Perspectives and Emerging Concepts in Intravaginal Drug Delivery
Approaches for effective and sustained drug delivery to the female reproductive tract (FRT) for treating a range of gynaecological conditions remain limited. The development of versatile delivery platforms, such as soluble gels (sol–gels) coupled with applicators/devices, holds considerable therapeutic potential for gynaecological conditions. Sol–gel systems, which undergo solution-to-gel transition, triggered by physiological conditions such as changes in temperature, pH, or ion composition, offer advantages of both solution- and gel-based drug formulations. Furthermore, they have potential to be used as a suitable drug delivery vehicle for other novel drug formulations, including micro- and nano-particulate systems, enabling the delivery of drug molecules of diverse physicochemical character. We provide an anatomical and physiological perspective of the significant challenges and opportunities in attaining optimal drug delivery to the upper and lower FRT. Discussion then focuses on attributes of sol–gels that can vastly improve the treatment of gynaecological conditions. The review concludes by showcasing recent advances in vaginal formulation design, and proposes novel formulation strategies enabling the infusion of a wide range of therapeutics into sol–gels, paving the way for patient-friendly treatment regimens for acute and chronic FRT-related conditions such as bacterial/viral infection control (e.g., STDs), contraception, hormone replacement therapy (HRT), infertility, and cancer
Effectiveness of unani regimen in protecting high risk population from COVID -19: A pilot study
248-254The coronavirus disease 2019 (COVID-19) pandemic caused
by the severe acute respiratory syndrome coronavirus 2 (SARSCoV-
2) has spread globally. COVID-19 presents varied clinical
features. The present study focuses on number of patients turning
COVID-19 positive, change in Immune Status Questionnaire
(ISQ) and WHO quality of life- Bref (WHO Qol – BREF) scales
after taking intervention. This open labelled, double arm,
controlled, interventional, clinical trial was conducted on highrisk
individuals i.e., those residing with a COVID-19 positive
member in the identified quarantine area. This twin armed study
was conducted on asymptomatic individuals exposed to COVID -
19. The test group were prescribed Unani poly-herbal decoction
together with Unani formulations Khamira Marwareed and
Tiryaq e Arba whereas the control group was not on any
intervention. The duration of intervention was 20 days; follow ups
were planned on day 10 and day 20. Of the 81 participants
enrolled, none of the patients turned COVID-19 positive.
However, 13.58% (n=11) developed COVID like symptoms and
70 patients completed the study. The mean age of the participants
was 41.42±16.9 years; however, majority of the participants were
18-28 years male with Damvi (Sanguine) temperament. The
quality of life of the intervention group improved significantly
however, the immune status in both the groups increased with P
<0.001. The Unani prophylactic regimen provides a 62% (relative
risk reduction) protection against COVID -19. This pilot study
paves for a study on a larger population. No adverse effects were
observed during the study. Absence of biochemical investigations
were limitations to the study